Docetaxel-induced mobilization of hematopoietic stem cells in a murine modelKinetics, dose titration, and toxicity

Experimental Hematology

Volumn 28, Issue 4, 2000, Pages 451-459

  Ojeifo, John O ^a   Wu, Aiguo G ^a   Miao, Yihong ^a   Herscowtiz, Herbert B ^b   Meehan, Kenneth R ^a  

^a Bone Marrow Transplantation Program   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Docetaxel; Hematopoietic stem cells; Mobilization; Priming chemotherapy

Indexed keywords

DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CLONING; CELL MOTILITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CELL COUNT; CELL DIVISION; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL MOBILIZATION; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; PACLITAXEL; SPLEEN; TAXOIDS;

ANIMALIA; MURINAE;

EID: 0034096091     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00130-2     Document Type: Article

References (48)

1. Keller G. Hematopoietic stem cells. Curr Opin Immunol. 4:1992;133.
2. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 81:1993;2844.
3. Spangrude G.J., Smith L., Uchida N., Ikuta K., Heimfeld S., Friedman J., Weissman I.L. Mouse hematopoietic stem cells. Blood. 78:1991;1395.
4. Sheridan W.P., Begley G.G., Turner C.A., Szer T., To L.B., Maber D., McGrath K.M., Mortstyn G., Fox R.M. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 339:1992;640.
5. Negram R.S., Kusnierz-Glaz C.R., Still B., Schriber T.R., Chao N.F., Long G.D., Hovie C., Hu W.W., Horning S.F., Brown R.W., Blume K.G., Strober S. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-hodgkin's lymphoma. Blood. 85:1995;3334.
6. Verma U.N., Yankelevich B., Hodgson J., Mazumder A. Effect of the in vitro priming for peripheral blood stem cells (PBSC) mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in a murine model. Bone Marrow Transplant. 19:1997;265.
7. Engelhardt M., Winkler J., Waller C., Lange W., Mertelsmann R., Henschler R. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor, and non-hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplant. 19:1997;529.
8. Demire T., Rowley S., Bucker C.D., Appelbaum F.R., Lilleby K., Starb R., Bensinger W.I. Peripheral-blood stem cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast cancer. J Clin Oncol. 13:1995;1714.
9. Fennelly D., Schneider J., Spriggs D., Bengala C., Hakes T., Reich L., Barakat J., Curtin J., Moore M.A.S., Hoskins W., Norton L., Crown J. Dose escalation of paclitaxel with high dose cyclophosphamide, with analysis of progenitor cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol. 13:1995;1160.
10. Rajagopal C., Areman E., Verma U.N., Meehan K., Cahill R., Frankel S.R., Kotula P., Hancock S., Sacher R., Mazunder A. Paclitaxel as a single agent is superior to cyclophosphamide for mobilizing CD34+ cells for stem cell transplantation. Blood. 86:1995;405a. (abstr).
11. Kaklamanis L., Leek R., Koukourakis M., Gatter K.C., Harris A.L. Loss of transporter in antigen processing I transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55:1995;5191.
12. Ogmundsdottir H.M., Petursdottir I., Gudmundsdottir I. Interactions between the immune system and breast cancer. Acta Oncol. 34:1995;647.
13. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1992;1795.
14. Marie-Christine B., Guenard D., Guerittte-Voegelein F., Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res. 51:1991;4845.
15. Israel R., Horwitz S.B. Studies with RP 56976 (Taxotere). a semisynthetic analogue of Taxol J Natl Cancer Inst. 83:1991;288.
16. Von Hoff D.D. The Taxoids. same roots, different drugs Semin Oncol. 24:1997;S13-S13.
17. Valero V., Holmes F.A., Walters R.S., Theriault R.L., Esparza L., Fraschini G., Fonseca G.A., Bellet R.E., Buzdar A.U., Hartobagyi G.N. Phase II trial of docetaxel. a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol. 13:1995;2886.
18. Ravdin P.M., Burris H.A. III, Cook G., Eisenberg P., Kane M., Bierman W.A., Mortimer J., Genevois E., Bellet R.E. Phase II trial of docetaxel in advanced anthracycline- resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 13:1995;2879.
19. Chan S, Fredrichs K, Noel D, Pinter T, Van Belle S, Voroblof D, Duarte F, Yelle L, Germa JR, Bodrogi I, Murray E, Walpole E, et al, on hehalf of the international 303 study group (1997) A phase III study of docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating-containing regimen. Breast Cancer Res Treat 46:23 (abstr).
20. Neben S, Marcus K, Mauch P (1993) Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 81:1960.
21. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Stober W (eds.) (1993) Isolation and fractionation of mononuclear cell populations. In: Current protocols in immunology, vol. 1, suppl. 8. New York: John Wiley & Sons, Inc., p. 3.1.3.
22. Colony assay of murine cells using methylcellulose- based medium. In. Instructional booklet manual version 2.0.0:1999;Stem Cell Technologies, Vancouver, Canada. 6p.
23. Bradley T.R., Hodgson G.S. Detection of primitive macrophage progenitor cells in mouse bone marrow. Blood. 54:1979;1446.
24. Huang S., Testappen L.W. Lymphoid and myeloid differentiation of a single human CD34+, HLA-DR+, CD38- hematopoietic stem cell. Blood. 83:1994;1515.
25. Verma U.N., Van den Blink B., Pilla R., Chawla J., Mazumder A., Herscowitz H.B., Meehan K.R. Paclitaxel versus cyclophosphamide in peripheral blood stem cell mobilization. comparative studies in a murine model Exp Hematol. 27:1999;553.
26. Rajagopal C., Verma U.N., Meehan K., Areman E., Bagg A., Cahill R., Mazumder A. Il-2-activated peripheral blood stem cell (PBSC) transplantation in breast cancer patients. patients with metastatic disease generate less potent cytotoxic effectors Proc ASCO. 14:1995;104. (abstr).
27. Areman E.M., Mazumder A., Kotula P.L., Verma U.N., Rajagopal C., Hancock C., Guevarra C., Djahanmir M., Sacher R.A., Meehan K.R. Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant. 18:1996;521.
28. Antman K.H., Rawlings P.A., Vaughan P.W., Pelz C.J., Fay J.W., Fields K.K., Freytes C.O., Gale R.P., Hillner B.E., Holland H.K., Kenedy M.J., Klein J.P.et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 15:1997;1870.
29. + peripheral blood cells in patients with poor-prognosis breast cancer. a randomized multicenter study Br J Cancer. 78:1998;913.
30. To L.B., Shepherd K.M., Haylock D.N., Dyson P.G., Charles P., Thorp D.L., Dale B.M., Dart G.W., Roberts M.M., Sage R.E., Juttner C.A. Single high doses of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from the peripheral blood. Exp Hematol. 18:1990;442.
31. Webb I.J., Eickhoff C.E., Elias A.D., Ayash L.J., Wheeler C.A., Schwartz G.N., Demetri G.D., Anderson K.C. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor. implications for timing and yield of hematopoietic progenitor cell collection Transfusion. 36:1996;160.
32. Cremer F.W., Kiel K., Wallmeier M., Haas R., Goldschmidt H., Moos M. Leukapheresis products in multiple myeloma. lower tumor load after mobilization with cyclophosphamide plus granulocyte colony stimulating factor (G-CSf) compared with G-CSF alone Exp Hematol. 26:1998;969.
33. Talmadge J.E., Reed E.C., Kessinger A., Kuszynski C.A., Perry G.A., Gordy C.L., Mills K.C., Thomas M.L., Pirruccello S.J., Letheby B.A., Arneson M.A., Jackson J.D. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant. 17:1996;101.
34. Shea T.C. Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. Semin Oncol. 24(suppl. 2):1997;S2-105.
35. Chuang L.T., Lotova E., Cook K.R., Munkarah A., Morris M., Wharton J.T. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug Taxol. Cancer Res. 54:1994;1286.
36. Braakhuis B.J.M., Hill B.T., Dietel M., Kelland L.R., Aapro M.S., Zoli W., Lelieveld P. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol), and cisplatin against human tumor and normal bone marrow cells. Anticancer Res. 14:1994;205.
37. Munkarah A., Chuang L., Lotzova E., Cook K., Morris M., Wharton J.T. Comparative studies of Taxol and Taxotere on tumor growth and lymphocyte functions. Gynecol Oncol. 55:1994;211.
38. Chaddock C.F., Apperley J.F., Wright E.G., Healy L.E., Bennett C.A., Evans M., Grimsley P.G., Gordon M.Y. Circulating stem cells in mice treated with cyclophosphamide. Blood. 80:1992;264.
39. Ogawa M., Shih J.P., Katayama N. Enrichment for primitive hematopoietic progenitors of marrow cells from 5-fluorouracil-treated mice and normal mice. Blood Cells. 20:1994;7.
40. Moore T., Huang S., Terstappen L.W.M.M., Bennett M., Kumar V. Expression of CD43 on murine and human pluripotent hematopoietic stem cells. J Immunol. 153:1994;4978.
41. Huang S., Testappen L.W.M.M. Analysis of bone marrow stem cells. Blood Cells. 20:1994;45.
42. 2 in patients with advanced cancer. Aust N Z J Med. 22:1992;660.
43. Kanfer E.J., McGuigan D., Samson D., Abboudi Z., Abrahamson G., Apperle J.F., Chilcott S., Craddock C., Davis J., MacDonald C., Olavarria E., Philpott N.et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells. efficacy and toxicity at three dose levels Br J Cancer. 78:1998;928.
44. Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Vrignaud P., Francois E., Bissery M.C., Levi F. Docetaxel chronopharmacology in mice. Cancer Res. 58:1998;3896.
45. Fennelly D.W., Aghajanian C., Shapiro F., O'Flaherty C., O'Connor K., Curtin J.P., Crown J.P., Hoskins W.J., Spriggs D.R. Dose escalation of paclitaxel with high-dose caboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol. 24(suppl. 2):1997;S2-26.
46. Gokhale P.C., Newsome J.T., Dritschilo A., Kasid U., Rahman A. Toxicity, histopathologic and pharmacokinetic evaluation of liposome-encapsulated paclitaxel and Taxol in mice and rabbits. Proc AACR. 40:1999;417. (abstr).
47. Bissery M.C. Preclinical pharmacology of docetaxel. Eur J Cancer. 31A(suppl. 4):1995;S1.
48. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - a phase II single-center study J Clin Oncol. 17:1999;1127.